Abstract: A method for detecting that a vehicle cabin is open includes broadcasting an acoustic signal through an aural transducer in the vehicle cabin, detecting a returned signal using an aural detector in the vehicle cabin, comparing the returned signal to an expected signal using processing circuitry in the vehicle, and determining that the vehicle cabin is open when the returned signal differs from the expected signal by a predetermined amount, and outputting an indication that the vehicle cabin is open. Outputting the indication that the vehicle cabin is open may include sending a wireless signal to a remote user device to alert a user that the vehicle cabin is open. The method may be performed in response to inclement weather, which may be detected by a rain sensor or by receiving, from an external wireless source, data indicating approaching inclement weather.

Abstract: This disclosure relates to a nebulization composition comprising tiotropium, or a pharmaceutically acceptable salt thereof, and indacaterol, or a pharmaceutically acceptable salt thereof. This disclosure also relates to a process for preparing such a composition and to methods of treating inflammatory and/or obstructive airway diseases using such a composition.

Abstract: The present invention relates to a nanoparticulate formulation comprising a microsomal prostaglandin E synthases-1 (“mPGES-1”) inhibitor. Particularly, the present invention relates to a nanoparticulate formulation comprising an mPGES-1 inhibitor and one or more surface stabilizers; a process for preparing such formulation; and its use in treating pain and inflammation in a subject.

Abstract: The present invention relates to a sterile pharmaceutical composition comprising indacaterol or a pharmaceutically acceptable salt thereof, for inhalation via nebulization to a subject in need thereof. The present invention also relates to a process of preparing such a pharmaceutical composition and the use of such compositions in the treatment of respiratory diseases.

Abstract: The present invention relates to a sterile pharmaceutical composition comprising tiotropium or a pharmaceutically acceptable salt thereof, for inhalation via nebulization to a subject (e.g. a human). The invention also relates to a process for preparing the pharmaceutical composition and its use in the treatment of respiratory diseases such as chronic obstructive pulmonary disease (COPD) in a subject.

Abstract: The present invention relates to a sterile pharmaceutical composition comprising tiotropium or a pharmaceutically acceptable salt thereof, for inhalation via nebulization to a subject (e.g. a human). The invention also relates to a process for preparing the pharmaceutical composition and its use in the treatment of respiratory diseases such as chronic obstructive pulmonary disease (COPD) in a subject.

Abstract: The present invention relates to a sterile pharmaceutical composition comprising tiotropium or a pharmaceutically acceptable salt thereof, for inhalation via nebulization to a subject (e.g. a human). The invention also relates to a process for preparing the pharmaceutical composition and its use in the treatment of respiratory diseases such as chronic obstructive pulmonary disease (COPD) in a subject.

Abstract: The present invention relates to a sterile pharmaceutical composition comprising tiotropium or a pharmaceutically acceptable salt thereof, for inhalation via nebulization to a subject (e.g. a human). The invention also relates to a process for preparing the pharmaceutical composition and its use in the treatment of respiratory diseases such as chronic obstructive pulmonary disease (COPD) in a subject.

Abstract: The present invention relates to a sterile pharmaceutical composition comprising tiotropium or a pharmaceutically acceptable salt thereof, for inhalation via nebulization to a subject (e.g. a human). The invention also relates to a process for preparing the pharmaceutical composition and its use in the treatment of respiratory diseases such as chronic obstructive pulmonary disease (COPD) in a subject.

Abstract: The present invention relates to a sterile pharmaceutical composition comprising tiotropium or a pharmaceutically acceptable salt thereof, for inhalation via nebulization to a subject (e.g. a human). The invention also relates to a process for preparing the pharmaceutical composition and its use in the treatment of respiratory diseases such as chronic obstructive pulmonary disease (COPD) in a subject.

Abstract: The present invention relates to a sterile pharmaceutical composition comprising tiotropium or a pharmaceutically acceptable salt thereof, for inhalation via nebulization to a subject (e.g. a human). The invention also relates to a process for preparing the pharmaceutical composition and its use in the treatment of respiratory diseases such as chronic obstructive pulmonary disease (COPD) in a subject.

Abstract: The present invention relates to therapeutic methods of administering tiotropium using a nebulizer. The present invention also relates to methods of treating inflammatory or obstructive airway diseases by administering a sterile nebulizable composition of tiotropium using a nebulizer.

Abstract: The present invention relates to a sterile pharmaceutical composition comprising tiotropium or a pharmaceutically acceptable salt thereof, for inhalation via nebulization to a subject (e.g. a human). The invention also relates to a process for preparing the pharmaceutical composition and its use in the treatment of respiratory diseases such as chronic obstructive pulmonary disease (COPD) in a subject.

Abstract: The present invention relates to a sterile pharmaceutical composition comprising tiotropium or a pharmaceutically acceptable salt thereof, for inhalation via nebulization to a subject (e.g. a human). The invention also relates to a process for preparing the pharmaceutical composition and its use in the treatment of respiratory diseases such as chronic obstructive pulmonary disease (COPD) in a subject.

Abstract: The present invention relates to a nanoparticulate formulation comprising a microsomal prostaglandin E synthases-1 (“mPGES-1”) inhibitor. Particularly, the present invention relates to a nanoparticulate formulation comprising an mPGES-1 inhibitor and one or more surface stabilizers; a process for preparing such formulation; and its use in treating pain and inflammation in a subject.

Abstract: The present invention relates to a sterile pharmaceutical composition comprising tiotropium or a pharmaceutically acceptable salt thereof, for inhalation via nebulization to a subject (e.g. a human). The invention also relates to a process for preparing the pharmaceutical composition and its use in the treatment of respiratory diseases such as chronic obstructive pulmonary disease (COPD) in a subject.

Abstract: A method and apparatus for hardware-based anamorphic video scaling. In one embodiment, the method includes the fetch of zero or more new input pixels according to an entry of an input control memory corresponding to a current output pixel. Once fetched, the zero or more new input pixels replace at least one stored input pixel of N, input pixels. Using the updated N, input pixels and an N, coefficient set selected according to an entry of a coefficient memory corresponding to the current output pixel, a pixel computation, such as, for example, an anamorphic scaling computation, is performed. In one embodiment, the anamorphic scaling is performed by subdividing an X×Y pixel frame into X/M M×Y pixel subframes. Other embodiments are described and claimed.

Abstract: The present patent application relates to a pharmaceutical composition comprising a fused pyrimidineone derivative having transient receptor potential modulating activity and a hydrophilic carrier.

Abstract: A method and apparatus for hardware-base edge handling in video post-processing. In one embodiment, the method includes the identification of at least one unstored input pixel required to compute an output pixel during output pixel computation. Once identified, a pixel value is generated for the at least one unstored input pixel according to a detected edge handling mode. The generation of the pixel value for the unstored input pixel is performed, in one embodiment, if a position of the unstored input pixel is outside a pixel frame boundary. For example, in one embodiment, for output pixel computation of a scaling operation, the frame boundaries include a left (top) edge and a right (bottom) edge for which input pixels required to compute output pixels at or near the frame boundaries do not exist. Other embodiments are described and claimed.

Abstract: A portion of a video frame is transferred via a memory burst transfer, from memory to an on-chip buffer. The on-chip buffer has a width that is the same as the memory burst width for the memory. Video processing is performed upon the transferred portion. Other embodiments are also described and claimed.